Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 20, 2025
Data Byte
FDA’s new and supplemental approvals in February
Springworks gets priority review voucher for Gomekli, first NovoLog biosimilar reaches market, and more
BioCentury | Jun 5, 2024
Emerging Company Profile
Tubulis: Enhancing ADC stability via new conjugation methods
German biotech raised series B2 round in March to push two highly stable ADC candidates into the clinic, and discover new payloads
BioCentury | Mar 23, 2024
Data Byte
EMA’s CHMP backs approval of Novartis’ complement drug
March decisions also include label extensions for UCB’s Bimzelx and Astellas’ Xtandi. Takeda pulls an application for Adcetris
BioCentury | Mar 12, 2024
Product Development
Clinical report: takeaways from Amylyx’s ALS journey
Plus: A comeback for Regulus? And updates from Acadia, MoonLake, Ventyx, Acelyrin, Sanofi and more
BioCentury | Mar 8, 2024
Product Development
Pfizer blends modality tools in new vision for oncology unit
Pharma outlines goals for oncology business as it moves to integrate ADC play Seagen
BioCentury | Apr 21, 2023
Product Development
ADC advances at AACR: target diversity, optimizing internalization
BioCentury’s analysis of the AACR 2023 abstracts highlights innovation in antibody-drug conjugate design
BioCentury | Apr 17, 2023
Deals
Merck enters precision immunology via $10.8B Prometheus takeout
December readouts in ulcerative colitis and Crohn’s disease drove up stock price, leading to $200-per-share deal
BioCentury | Feb 4, 2023
Market Access
Rare diseases, MNCs grow presence on China’s NRDL
Even with big price reductions, China’s national reimbursement list is a lure for drug developers around the globe
BioCentury | Dec 13, 2022
Product Development
Dec. 12 Quick Takes: Setbacks at ASH for Adicet and Lava
Plus: Updates from Magenta, CSL, Hemgenix, Affimed, Kymera and more
BioCentury | Nov 4, 2022
Deals
Nov. 4 Quick Takes: Bayer returns rights to Ionis’ antithrombotic
Plus Vicore gains on IPF data and updates from Acrivon, BioAtla, Novadip and more
Items per page:
1 - 10 of 316